# Clinical Trials Data EGFR - Document 58

# CPCT-05 Biopsy Protocol Patient Selection

## Clinical Trial: https://clinicaltrials.gov/study/NCT01904916

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Locally advanced (incurable) or metastatic cancer from a histological or cytological proven solid tumor\n\* Indication for systemic treatment with anti-cancer agents (with no treatment options with curative intent)\n\* Measurable locally advanced (incurable) or metastatic lesion(s), according to RECIST 1.1 criteria.\n\* Safe biopsy of a metastatic or locally advanced lesion possible\n\* No contraindications for lidocaine (or its derivatives) and/or midazolam and/or phentanyl\n\* Adequate organ function\n\* WHO performance status 0-2\n\* Age \\> 18 yr\n\* Expected adequacy to follow up\n\* Written informed consent\n\nExclusion Criteria:\n\n\u2022 If one or more of the above mentioned inclusion criteria is not met",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no specific mention of the EGFR gene mutation either as an inclusion or exclusion criterion. As such, a patient with an EGFR gene mutation is not automatically excluded based on the criteria listed. The eligibility primarily depends on the broader criteria detailed, such as having a locally advanced or metastatic solid tumor, the ability to undergo a biopsy, adequate organ function, and so on.  
  
Ultimately, whether a patient with an EGFR mutation would be eligible would depend on the broadness of the trial's intended molecular targets or therapeutic focus, as it does not seem to specifically exclude mutations or make them a primary focal point. It is always best to verify with the trial's clinical research coordinators or the oncology team managing the patient to ensure all specific medical details are considered along with the trial's goals.